"AC133 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of the prominin family, AC133 Antigen is a 5-transmembrane antigen occurring as several isoforms produced by alternative splicing which are processed into mature forms. In humans, it is expressed as a subset of CD34 (bright) human hematopoietic stem cells and CD34 positive leukemias. Functionally, it is associated with roles in cell differentiation, proliferation, and apoptosis. Specifically, it regulates the organization of apical plasma membrane in epithelial cells, disk morphogenesis during early retinal development, MAPK and Akt signaling pathways, and in cholesterol metabolism.
| Descriptor ID |
D000071916
|
| MeSH Number(s) |
D12.776.395.550.007 D12.776.543.550.023
|
| Concept/Terms |
AC133 Antigen- AC133 Antigen
- Antigen, AC133
- CD133 Antigen
- Antigen, CD133
- PROML1
- Prominin
- Prominin-1
- Prominin 1
- Prominin-Like PROML1
- Prominin Like PROML1
- AC133-1 Antigen
- AC133 1 Antigen
- Antigen, AC133-1
- Fudenine
|
Below are MeSH descriptors whose meaning is more general than "AC133 Antigen".
Below are MeSH descriptors whose meaning is more specific than "AC133 Antigen".
This graph shows the total number of publications written about "AC133 Antigen" by people in this website by year, and whether "AC133 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 2 | 2 |
| 2011 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "AC133 Antigen" by people in Profiles.
-
Development of CD133 Targeting Multi-Drug Polymer Micellar Nanoparticles for Glioblastoma - In Vitro Evaluation in Glioblastoma Stem Cells. Pharm Res. 2021 Jun; 38(6):1067-1079.
-
A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells. Cell Rep. 2019 03 12; 26(11):3061-3075.e6.
-
Cardiac glycosides suppress the maintenance of stemness and malignancy via inhibiting HIF-1a in human glioma stem cells. Oncotarget. 2017 Jun 20; 8(25):40233-40245.
-
Lipid nanocapsule functionalization by lipopeptides derived from human papillomavirus type-16 capsid for nucleic acid delivery into cancer cells. Int J Pharm. 2013 Oct 01; 454(2):756-64.
-
Growth kinetics of CD133-positive prostate cancer cells. Prostate. 2013 May; 73(7):724-33.
-
Gefitinib resistance in HCC mahlavu cells: upregulation of CD133 expression, activation of IGF-1R signaling pathway, and enhancement of IGF-1R nuclear translocation. J Cell Physiol. 2012 Jul; 227(7):2947-52.
-
In vitro expansion of human glioblastoma cells at non-physiological oxygen tension irreversibly alters subsequent in vivo aggressiveness and AC133 expression. Int J Oncol. 2012 Apr; 40(4):1220-9.
-
The importance of the stem cell marker prominin-1/CD133 in the uptake of transferrin and in iron metabolism in human colon cancer Caco-2 cells. PLoS One. 2011; 6(9):e25515.
-
Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions. Cell Death Dis. 2011 Sep 01; 2:e200.
-
Development and characterization of immuno-nanocarriers targeting the cancer stem cell marker AC133. Int J Pharm. 2012 Feb 14; 423(1):93-101.